SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Aigner Clemens)
 

Sökning: WFRF:(Aigner Clemens) > Potential subtype-s...

  • Horvath, LillaNational Korányi Institute for Tuberculosis and Pulmonology, Hungary (författare)

Potential subtype-specific therapeutic approaches in small cell lung cancer

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • 2024
  • 6 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:128947c3-7e30-4c39-807f-778fbcd79cfa
  • https://lup.lub.lu.se/record/128947c3-7e30-4c39-807f-778fbcd79cfaURI
  • https://doi.org/10.1097/CCO.0000000000001005DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:for swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • PURPOSE OF REVIEW: Small cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies with an especially dismal prognosis. While the detection of various targetable driver mutations and immune checkpoints have revolutionized the treatment of non-small cell lung cancer (NSCLC), there has been only modest therapeutic innovation over the past decades in SCLC. In this review, we aim to provide a brief summary on the clinical relevance of recent research findings, which could soon pave the way towards a more personalized and targeted management of SCLC patients. RECENT FINDINGS: Substantial research on the biological and molecular heterogeneity of SCLC has been conducted in the last years. Recent results from comprehensive profiling studies have shown that unique major SCLC subtypes can be distinguished based on the relative expression of key transcription regulators (ASCL1, NEUROD1, POU2F3) or distinct inflammatory features. Understanding the differing molecular characteristics of these distinct subtypes has resulted in the identification of specific therapeutic vulnerabilities. SUMMARY: The recently introduced molecular SCLC subtype classification represents a substantial progress towards a personalized and more efficacious approach in SCLC. The consequences of this paradigm shift provide hope for improved patient care and clinical outcomes in this exceptionally lethal thoracic malignancy.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Lang, ChristianMedical University of Vienna (författare)
  • Boettiger, Kristiina (författare)
  • Aigner, Clemens (författare)
  • Dome, BalazsLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,National Korányi Institute for Tuberculosis and Pulmonology, Hungary,Semmelweis University(Swepub:lu)ba1464do (författare)
  • Megyesfalvi, ZsoltNational Korányi Institute for Tuberculosis and Pulmonology, Hungary,National Institute of Oncology, Budapest (författare)
  • National Korányi Institute for Tuberculosis and Pulmonology, HungaryMedical University of Vienna (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Current Opinion in Oncology36:1, s. 51-561040-8746

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy